financetom
Business
financetom
/
Business
/
Israel's Leviathan gas field to resume operations after shutdown during Iran conflict
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Israel's Leviathan gas field to resume operations after shutdown during Iran conflict
Jun 25, 2025 1:55 AM

JERUSALEM, June 25 (Reuters) - Israel's NewMed

said on Wednesday the Leviathan natural gas field

that supplies gas to Egypt and Jordan, shut down nearly two

weeks ago due to the Iran-Israel conflict, would resume

operations in the next few hours.

Two of Israel's three gas fields - Chevron ( CVX )-operated

Leviathan and Energean's ( EERGF ) Karish - off its Mediterranean coast

that provide the bulk of exports to Egypt and Jordan have been

shut since June 13.

That left in operation only the older Tamar field, used

mainly for domestic supplies.

Israel and Iran agreed to a ceasefire on Tuesday. Israel's

Energy Ministry said that after a security assessment, Energy

Minister Eli Cohen had ordered the opening of Leviathan and

Karish.

The ministry said resuming regular operations at the rigs

will "enable the supply of natural gas to all customers", the

resumption of gas exports to neighboring countries, a rise in

state tax revenues, and greater flexibility in managing the

electricity and industrial sectors.

Israeli gas accounts for about 15-20% of Egypt's

consumption, data from the Joint Organisations Data Initiative

(JODI) shows. The disruption to Israel's gas supply had led

Egyptian fertilizer producers to halt operations.

Cohen told Reuters last week that Israel would resume

natural gas exports once the country's military deemed it safe

to do so.

Leviathan, a deep-sea field with huge deposits, came online

at the end of 2019 and produces 12 billion cubic metres of gas

per year for sale to Israel, Egypt and Jordan. That will rise to

some 14 bcm in 2026.

In addition to Chevron ( CVX ) and NewMed, Ratio Energies

is also a partner in Leviathan.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Infleqtion and Churchill Capital Corp X Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
Infleqtion and Churchill Capital Corp X Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
Nov 4, 2025
BOULDER, Colo. & NEW YORK--(BUSINESS WIRE)-- Infleqtion, a global leader in neutral-atom–based quantum technology, and Churchill Capital Corp X ( CCCX ) , a publicly traded special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) on October 29, 2025. The submission...
Astronics Q3 sales miss estimates
Astronics Q3 sales miss estimates
Nov 4, 2025
Overview * Astronics ( ATRO ) Q3 sales up 3.8% to $211.4 mln, missing analyst expectations * Company reports Q3 net loss of $11.1 mln due to refinancing-related charges * Adjusted EBITDA for Q3 was $32.7 mln, or 15.5% of sales Outlook * Company expects Q4 revenue between $225 mln and $235 mln * Astronics ( ATRO ) sees 2025...
Equitable Holdings Q3 EPS misses estimates
Equitable Holdings Q3 EPS misses estimates
Nov 4, 2025
Overview * Equitable Holdings ( EQH ) reports Q3 net loss of $1.3 bln due to life reinsurance impact * Adjusted EPS for Q3 misses analyst expectations * Assets under management rose 7% yr/yr to $1.1 trillion Outlook * Equitable Holdings ( EQH ) maintains confidence in achieving 2027 financial targets * Company plans $1.5 bln capital deployment for growth...
Niagen Bioscience Q3 sales beat estimates on strong e-commerce performance 
Niagen Bioscience Q3 sales beat estimates on strong e-commerce performance 
Nov 4, 2025
Overview * Niagen Bioscience ( NAGE ) Q3 net sales rise 33%, beating analyst expectations * Adjusted EBITDA for Q3 increases 120%, reflecting improved operational performance * Company reaffirms full-year net sales growth outlook of 25% to 30% Outlook * Niagen Bioscience ( NAGE ) reaffirms 2025 net sales growth of 25% to 30% y-o-y * Company expects 2025 gross...
Copyright 2023-2026 - www.financetom.com All Rights Reserved